1. Krachmer JH, Mannis MJ, Holland EJ. Cornea. 2nd ed. Philadelphia: Elsevier & Mosby;2005. p. 115–46.
2. Ohji M, SundarRaj N, Thoft RA. Transforming growth factor-beta stimulates collagen and fibronectin synthesis by human corneal stromal fibroblasts in vitro. Curr Eye Res. 1993; 12:703–9.
3. Jester JV, Barry-Lane PA, Cavanagh HD, Petroll WM. Induction of alpha-smooth muscle actin expression and myofibroblast transfo-rmation in cultured corneal keratocytes. Cornea. 1996; 15:505–16.
4. Fini ME, Girard MT, Matsubara M, Bartlett JD. Unique regulation of the matrix metalloproteinase, gelatinase B. Invest Ophthalmol Vis Sci. 1995; 36:622–33.
5. Grant MB, Khaw PT, Schultz GS, et al. Effects of epidermal growth factor, fibroblast growth factor, and transforming growth factor-beta on corneal cell chemotaxis. Invest Ophthalmol Vis Sci. 1992; 33:3292–301.
6. Desmouliere A, Rubbia-Brandt L, Grau G, Gabbiani G. Heparin induces alpha-smooth muscle actin expression in cultured fibroblasts and in granulation tissue myofibroblasts. Lab Invest. 1992; 67:716–26.
7. Garana RM, Petroll WM, Chen WT, et al. Radial keratotomy. II. Role of the myofibroblast in corneal wound contraction. Invest Ophthalmol Vis Sci. 1992; 33:3271–82.
8. Petroll WM, Cavanagh HD, Barry P, et al. Quantitative analysis of stress fiber orientation during corneal wound contraction. J Cell Sci. 1993; 104:353–63.
Article
9. Shah M, Foreman DM, Ferguson MW. Neutralizing antibody to TFG-beta 1,2 reduces cutaneous scarring in adult rodents. J Cell Sci. 1994; 107:1137–57.
10. Cordeiro MF, Mead A, Ali RR, et al. Novel antisense oligo-nucleotides targeting TGF-beta inhibit in vivo scarring and improve surgical outcome. Gene Ther. 2003; 10:59–71.
11. Cordeiro MF, Gay JA, Khaw PT. Human anti-transforming growth factor-beta2 antibody: a new glaucoma anti-scarring agent. Invest Ophthalmol Vis Sci. 1999; 40:2225–34.
12. Siriwardena D, Khaw PT, King AJ, et al. Human antitransforming growth factor beta (2) monoclonal antibody-a new modulator of wound healing in trabeculectomy: a randomized placebo controlled clinical study. Ophthalmology. 2002; 109:427–31.
13. Moller-Pedersen T, Cavanagh HD, Petroll WM, Jester JV. Neutralizing antibody to TGF-beta modulates stromal fibrosis but not regression of photoablative effect following PRK. Curr Eye Res. 1998; 17:736–47.
14. Mathers WD, Lemp MA. Theevolution of scarring following penetrating keratoplasty. Cavanogh HD, editor. The cornea: Trans-actions of the World congress on the Cornea III. New York: Raven Press;1988. Ⅱ:chap. 16.
15. Goodman GL, Trokel SL, Stark WJ, et al. Corneal healing following laser refractive keratectomy. Arch Ophthalmol. 1989; 107:1799–803.
Article
16. Thompson NL, Bazoberry F, Speir EH, et al. Transforming growth factor beta-1 in acute myocardial infarction in rats. Growth Factors. 1988; 1:91–9.
Article
17. Wahl SM. Transforming growth factor beta (TGF-beta) in inflammation: a cause and a cure. J Clin Immunol. 1992; 12:61–74.
18. Mita T, Yamashita H, Kaji Y, et al. Effects of transforming growth factor beta on corneal epithelial and stromal cell function in a rat wound healing model after excimer laser keratectomy. Graefes Arch Clin Exp Ophthalmol. 1998; 236:834–43.
19. Hayashi K, Frangieh G, Wolf G, Kenyon KR. Expression of transforming growth factor-beta in wound healing of vitamin A-deficient rat corneas. Invest Ophthalmol Vis Sci. 1989; 30:239–47.
20. Rochels R, Busse WD. In vivo evidence for the chemotactic activity of cyclooxygenase- and lipoxygenase-dependent compounds using a corneal implantation technique. Ophthalmic Res. 1984; 16:194–7.
Article
21. Azar DT, Hahn TW, Jain S, et al. Matrix metalloproteinases are expressed during wound healing after excimer laser keratectomy. Cornea. 1996; 15:18–24.
Article
22. Rieck P, Assouline M, Savoldelli M, et al. Recombinant human basic fibroblast growth factor (Rh-bFGF) in three different wound models in rabbits: corneal wound healing effect and pharmacology. Exp Eye Res. 1992; 54:987–98.
Article
23. Ohno K, Mitooka K, Nelson LR, et al. Keratocyte activation and apoptosis in transplanted human corneas in a xenograft model. Invest Ophthalmol Vis Sci. 2002; 43:1025–31.
24. Fini ME. Keratocyte and fibroblast phenotypes in the repairing cornea. Prog Retin Eye Res. 1999; 18:529–51.
Article
25. Eckes B, Kessler D, Aumailley M, Krieg T. Interactions of fibroblasts with the extracellular matrix: implications for the understanding of fibrosis. Springer Semin Immunopathol. 1999; 21:415–29.
Article
26. Davison PF, Galbavy EJ. Fluorescent dyes demonstrate the uniform expansion of the growing rabbit cornea. Invest Ophthalmol Vis Sci. 1985; 26:1202–9.
27. Davison PF, Galbavy EJ. Connective tissue remodeling in corneal and scleral wounds. Invest Ophthalmol Vis Sci. 1986; 27:1478–84.
28. Tuft SJ, Zabel RW, Marshall J. Corneal repair following keratectomy. A comparison between conventional surgery and laser photoablation. Invest Ophthalmol Vis Sci. 1989; 30:1769–77.
29. Jain S, Hahn TW, McCally RL, Azar DT. Antioxidants reduce corneal light scattering after excimer keratectomy in rabbits. Lasers Surg Med. 1995; 17:160–5.
Article
30. Kim TI, Lee SY, Pak JH, et al. Mitomycin C, ceramide, and 5-fluorouracil inhibit corneal haze and apoptosis after PRK. Cornea. 2006; 25:55–60.
Article
31. Carones F, Vigo L, Scandola E, Vacchini L. Evaluation of the prophylactic use of mitomycin-C to inhibit haze formation after photorefractive keratectomy. J Cataract Refract Surg. 2002; 28:2088–95.
Article
32. Safianik B, Ben-Zion I, Garzozi HJ. Serious corneoscleral complications after pterygium excision with mitomycin C. Br J Ophthalmol. 2002; 86:357–8.
Article
33. Hayasaka S, Iwasa Y, Nagaki Y, et al. Late complications after pterygium excision with high dose mitomycin C instillation. Br J Ophthalmol. 2000; 84:1081–2.
Article